Effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on cardiovascular alterations in endotoxemia

被引:13
作者
Azab, AN
Kobal, S
Rubin, M
Kaplanski, J [1 ]
机构
[1] Ben Gurion Univ Negev, Dept Clin Pharmacol, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
[2] Soroka Univ, Med Ctr, Dept Cardiol, Beer Sheva, Israel
关键词
lipopolysaccharide; rats; endotoxemic; endotoxemia; cyclooxygenase; interleukin-1; beta;
D O I
10.1159/000082470
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Prostanoids and cytokines are known to play a pivotal role in the mechanisms leading to endotoxin-induced cardiovascular failure. We investigated the effect of nimesulide ( NIM), a selective cyclooxygenase-2 ( COX-2) inhibitor, on the cardiovascular alterations occurring during endotoxemia, and on prostaglandin E-2 ( PGE(2)), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) levels in endotoxemic rats. NIM significantly reduced endotoxin-induced elevation of plasma and myocardial levels of TNF-alpha, but not those of IL-1beta. Searching for the mechanism underlying the anti-TNF-alpha effect of NIM, it was found that the drug reduced nuclear factor kappa B activation through diminished nuclear levels of p-65 accompanied by a protective effect against the cardiovascular alterations and mortality seen during endotoxemia. In addition, the inhibitory effect of NIM on endotoxin-induced elevation in plasma and hypothalamic levels of PGE2 was noteworthy, and this may suggest that the large amounts of PGE2 observed during endotoxemia are mainly produced via COX-2. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 45 条
[1]
EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]
Abraham E, 1998, LANCET, V351, P929
[3]
p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial [J].
Abraham, E ;
Glauser, MP ;
Butler, T ;
Garbino, J ;
Gelmont, D ;
Laterre, PF ;
Kudsk, K ;
Bruining, HA ;
Otto, C ;
Tobin, E ;
Zwingelstein, C ;
Lesslauer, W ;
Leighton, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19) :1531-1538
[4]
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients [J].
Abraham, E ;
Laterre, PF ;
Garbino, J ;
Pingleton, S ;
Butler, T ;
Dugernier, T ;
Margolis, B ;
Kudsk, K ;
Zimmerli, W ;
Anderson, P ;
Reynaert, M ;
Lew, D ;
Lesslauer, W ;
Passe, S ;
Cooper, P ;
Burdeska, A ;
Modi, M ;
Leighton, A ;
Salgo, M ;
Van der Auwera, P .
CRITICAL CARE MEDICINE, 2001, 29 (03) :503-510
[5]
ALMQVIST PM, 1984, CIRC SHOCK, V14, P129
[6]
Effects of ibuprofen on the physiology and survival of hypothermic sepsis [J].
Arons, MM ;
Wheeler, AP ;
Bernard, GR ;
Christman, BW ;
Russell, JA ;
Schein, R ;
Summer, WR ;
Steinberg, KP ;
Fulkerson, W ;
Wright, P ;
Dupont, WD ;
Swindell, BB .
CRITICAL CARE MEDICINE, 1999, 27 (04) :699-707
[7]
Nimesulide prevents lipopolysaccharide-induced elevation in plasma tumor necrosis factor-α in rats [J].
Azab, A ;
Fraifeld, V ;
Kaplanski, J .
LIFE SCIENCES, 1998, 63 (23) :PL323-PL327
[8]
A reduction of tumor necrosis factor-α in paw exudate of lipopolysaccharide treated rats by nimesulide [J].
Azab, AN ;
Kaplanski, J .
LIFE SCIENCES, 2001, 68 (14) :1667-1675
[9]
The effects of ibuprofen on the physiology and survival of patients with sepsis [J].
Bernard, GR ;
Wheeler, AP ;
Russell, JA ;
Schein, R ;
Summer, WR ;
Steinberg, KP ;
Fulkerson, WJ ;
Wright, PE ;
Christman, BW ;
Dupont, WD ;
Higgins, SB ;
Swindell, BB .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :912-918
[10]
Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself [J].
Beutler, B ;
Kruys, V .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 :S1-S8